Clinical Trial

A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with other antitumor therapies in advanced solid tumors to explore the reasonable dosage, safety and efficacy of SHR-A2102 for advanced solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-20.
Status change: Not Yet Recruiting → Recruiting 2025-04-21
Trial Details
NCT Number NCT06895928
Lead Sponsor Shanghai Hengrui Pharmaceutical Co., Ltd.
Conditions Advanced Solid Tumors
Enrollment 400 participants
Start Date 2025-03-28
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-04-22